Literature DB >> 18273720

Psoriasis comorbidities.

Alice B Gottlieb1, Chun Chao, Frank Dann.   

Abstract

Psoriasis is a chronic and debilitating inflammatory disease associated with serious comorbidities. Psoriasis can have a significant impact on a patient's quality of life and is associated with loss of productivity, depression, and an increased prevalence of malignancy. Emerging comorbidities of psoriasis include cardiovascular disease and metabolic syndrome. Psoriasis patients have an increased prevalence of the core components of metabolic syndrome, including obesity, dyslipidemia, and insulin resistance. The relationship between psoriasis and comorbidities such as metabolic syndrome and cardiovascular disease is likely linked to the underlying chronic inflammatory nature of psoriasis. The molecular mechanisms involved in psoriasis-associated dysregulation of metabolic function are believed to be due, in large part, to the action of increased levels of proinflammatory factors, such as tumor necrosis factor-alpha, that are central to the pathogenesis of psoriasis. Recent studies investigating the effects of tumor necrosis factor antagonists on the treatment of cardiovascular disease and metabolic syndrome support this concept.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18273720     DOI: 10.1080/09546630701364768

Source DB:  PubMed          Journal:  J Dermatolog Treat        ISSN: 0954-6634            Impact factor:   3.359


  50 in total

1.  A practical approach to monitoring patients on biological agents for the treatment of psoriasis.

Authors:  Jason J Emer; Amylynne Frankel; Joshua A Zeichner
Journal:  J Clin Aesthet Dermatol       Date:  2010-08

Review 2.  Update on the natural history and systemic treatment of psoriasis.

Authors:  Stephen K Richardson; Joel M Gelfand
Journal:  Adv Dermatol       Date:  2008

3.  The brain-skin connection: role of psychosocial factors and neuropeptides in psoriasis.

Authors:  Ben P Chapman; Jan Moynihan
Journal:  Expert Rev Clin Immunol       Date:  2009-11       Impact factor: 4.473

4.  Association of Skin Psoriasis and Somatic Comorbidity With the Development of Psychiatric Illness in a Nationwide Swedish Study.

Authors:  Kirk Geale; Martin Henriksson; Jussi Jokinen; Marcus Schmitt-Egenolf
Journal:  JAMA Dermatol       Date:  2020-07-01       Impact factor: 10.282

5.  Association of Psoriasis With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.

Authors:  Yun Fu; Cheng-Han Lee; Ching-Chi Chi
Journal:  JAMA Dermatol       Date:  2018-12-01       Impact factor: 10.282

6.  Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis.

Authors:  Sauzanne Khalilieh; Azher Hussain; Diana Montgomery; Vanessa Levine; Peter M Shaw; Inga Bodrug; Lally Mekokishvili; Candice Bailey-Smith; Xiaoli S Glasgow; Amy Cheng; Monika Martinho; Marian Iwamoto
Journal:  Br J Clin Pharmacol       Date:  2018-07-31       Impact factor: 4.335

7.  Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept.

Authors:  James E Signorovitch; Eric Q Wu; Andrew P Yu; Charles M Gerrits; Evan Kantor; Yanjun Bao; Shiraz R Gupta; Parvez M Mulani
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

8.  Evaluation of subclinical atherosclerosis in Egyptian psoriatic patients.

Authors:  Raghda Ghonimy Elsheikh; Tarek El-Sayed Amin; Amal Ahmad El-Ashmawy; Samah Ibrahim Abd El-Fttah Abdalla
Journal:  J Saudi Heart Assoc       Date:  2013-12-18

Review 9.  Psychoneuroimmunology: the example of psoriasis.

Authors:  J Moynihan; E Rieder; F Tausk
Journal:  G Ital Dermatol Venereol       Date:  2010-04       Impact factor: 2.011

10.  Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trials.

Authors:  Kim A Papp; James Signorovitch; Karthik Ramakrishnan; Andrew P Yu; Shiraz R Gupta; Yanjun Bao; Parvez M Mulani
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.